top of page

Pipeline
Who We Are
NanO₂
Glioblastoma
Publications
News
Contact
More

Use tab to navigate through the menu items.

The latest from NuvOx

All Posts
News
Events
Publications
Hemorrhagic Shock
Mechanism Of Action
Myocardial Infarction
Oncology
Pharmacokinetics
Stroke
Traumatic Brain Injury
Other

Search

NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada

Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to...

Aug 14, 2023

NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial

Tucson, AZ, May 30, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat...

Jun 7, 2023

NuvOx Receives SPAN Grant

NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion Tucson, AZ, ...

Apr 19, 2023

NuvOx Newly Issued US Patent

NuvOx Newly Issued US Patent

NuvOx Newly Issued US Patent

The issued patent has claims for methods of use of DDFPe for stroke treatment.

Mar 5, 2023

NuvOx Pharma Presents at AZ BIO White Hat Event

NuvOx Pharma Presents at AZ BIO White Hat Event

NuvOx Pharma Presents at AZ BIO White Hat Event

Oct 11, 2022

NuvOx Therapeutics

1635 E 18th Street

Tucson, Arizona 85719

Terms & Conditions

© 2025 NuvOx Therapeutics

Pipeline
Who We Are
NanO₂
Glioblastoma

Publications
News
Contact
Careers

bottom of page